Article
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
Journal of internal medicine - 1 Jun 2016
Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo J L, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva J-P, Rolandi E, Rossini P M, Schönknecht P, Soricelli A, Tsolaki M, Visser P J, Wiltfang J, Richardson J C, Bordet R, Blin O, Frisoni G B
Abstract excerpt
BACKGROUND: In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. OBJECTIVE: To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.